RxDoctor Payments Data

Subba Vanga, MD

Interventional Cardiology · Conyers, GANPI 1265698013

Payments from drug & device makers

$3,684in general payments, 2019–2025

Across 161 payments — averaging $22.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$901
  • Amgen$365
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$268
  • Boston Scientific$253
  • Boehringer Ingelheim$249
  • Merck$200
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,684100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,684 in reported general payments places this provider in the 25th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$108,203
Medicare patients
1,049
Services billed
2,435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban190$193,162
XareltoRivaroxaban46$64,272
EntrestoSacubitril/Valsartan25$40,815
Repatha SureclickEvolocumab19$27,368
BrilintaTicagrelor15$12,681
Metoprolol Succinate203$2,510
Atorvastatin Calcium221$1,717
Losartan Potassium159$1,142
Carvedilol109$1,064
Rosuvastatin Calcium65$846
ClopidogrelClopidogrel Bisulfate116$839
Hydralazine Hcl50$602
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide44$595
Amlodipine Besylate95$551
Potassium Chloride13$416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$157$193,162190 claims
Johnson & JohnsonXarelto$50$64,27246 claims
NovartisEntresto$901$40,81525 claims
AstraZenecaBrilinta$114$12,68115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Conyers

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →